BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 16584118)

  • 1. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.
    Ananthan S
    AAPS J; 2006 Mar; 8(1):E118-25. PubMed ID: 16584118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterodimerization of mu and delta opioid receptors: A role in opiate synergy.
    Gomes I; Jordan BA; Gupta A; Trapaidze N; Nagy V; Devi LA
    J Neurosci; 2000 Nov; 20(22):RC110. PubMed ID: 11069979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
    Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
    Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bifunctional μ opioid and σ
    Zhuang T; Xiong J; Hao S; Du W; Liu Z; Liu B; Zhang G; Chen Y
    Eur J Med Chem; 2021 Nov; 223():113658. PubMed ID: 34175542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
    Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
    ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.
    Schiller PW; Fundytus ME; Merovitz L; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Coderre TJ
    J Med Chem; 1999 Sep; 42(18):3520-6. PubMed ID: 10479285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
    Healy JR; Bezawada P; Griggs NW; Devereaux AL; Matsumoto RR; Traynor JR; Coop A; Cunningham CW
    Bioorg Med Chem Lett; 2017 Feb; 27(3):666-669. PubMed ID: 28011222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The mu, delta and kappa properties of various opioids].
    Ohta S; Niwa M; Nozaki M; Hattori M; Shimonaka H; Dohi S
    Masui; 1995 Sep; 44(9):1228-32. PubMed ID: 8523655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
    Liu JG; Prather PL
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic opioid peptide agonists and antagonists obtained via ring-closing metathesis.
    Berezowska I; Lemieux C; Chung NN; Wilkes BC; Schiller PW
    Chem Biol Drug Des; 2009 Oct; 74(4):329-34. PubMed ID: 19694755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
    Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
    Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-peptidic δ opioid receptor agonists and antagonists (2000 - 2012).
    Fujii H; Takahashi T; Nagase H
    Expert Opin Ther Pat; 2013 Sep; 23(9):1181-208. PubMed ID: 23705966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.
    Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI
    ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
    Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
    Anand JP; Kochan KE; Nastase AF; Montgomery D; Griggs NW; Traynor JR; Mosberg HI; Jutkiewicz EM
    Br J Pharmacol; 2018 Jun; 175(11):2013-2027. PubMed ID: 29352503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
    Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S
    J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.